2
|
Yamane M, Igarashi F, Yamauchi T, Nakagawa T. Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout. Xenobiotica 2020; 51:61-71. [PMID: 32813611 DOI: 10.1080/00498254.2020.1812012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
UR-1102, a novel uricosuric agent for treating gout, has been confirmed to exhibit a pharmacological effect in patients. We clarified its metabolic pathway, estimated the contribution of each metabolic enzyme, and assessed the impact of genetic polymorphisms using human in vitro materials. Glucuronide, sulfate and oxidative metabolites of UR-1102 were detected in human hepatocytes. The intrinsic clearance by glucuronidation or oxidation in human liver microsomes was comparable, but sulfation in the cytosol was much lower, indicating that the rank order of contribution was glucuronidation ≥ oxidation > sulfation. Recombinant UGT1A1 and UGT1A3 showed high glucuronidation of UR-1102. We took advantage of a difference in the inhibitory sensitivity of atazanavir to the UGT isoforms and estimated the fraction metabolised (fm) with UGT1A1 to be 70%. Studies using recombinant CYPs and CYP isoform-specific inhibitors showed that oxidation was mediated exclusively by CYP2C9. The effect of UGT1A1 and CYP2C9 inhibitors on UR-1102 metabolism in hepatocytes did not differ markedly between the wild type and variants.
Collapse
Affiliation(s)
- Mizuki Yamane
- Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
| | | | | | - Toshito Nakagawa
- Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan
| |
Collapse
|
3
|
He H, Zhang Y, Zhao D, Jiang J, Xie B, Ma L, Liu X, Yu C. Osthole inhibited the activity of CYP2C9 in human liver microsomes and influenced indomethacin pharmacokinetics in rats. Xenobiotica 2020; 50:939-946. [PMID: 32238050 DOI: 10.1080/00498254.2020.1734882] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Osthol, a pharmacologically active ingredient in various traditional Chinese medicines, is predominantly metabolized by CYP2C9. It may be co-administered with other drugs which are metabolized by CYP2C9 in clinical medicine. However, CYP2C9*1/*2/*3 genotype on the pharmacokinetics of osthole and its metabolic diversity between rat and human are unclear.In this study, we investigated the effects of osthole on enzyme activity of CYP2C11/CYP2C9 in rat liver microsomes (RLMs) and human liver microsomes (HLMs), to distinguish metabolic manner of osthole in different species. Interestingly, we found that osthole inhibits the activity of CYP2C11 in a non-competitive manner in RLMs, while inhibits CYP2C9 activity in a competitive manner in pooled HLMs. Then, the effects of CYP2C9*1/*2/*3 allele on the pharmacokinetics of osthole were identified. In human CYP2C9 isoform, the Ki value of 21.93 μM (CYP2C9*1), 18.10 μM (CYP2C9*2), 13.12 μM (CYP2C9*3) indicate that there are individual differences in the inhibition of osthole on CYP2C9 activity.We investigated how the indomethacin pharmacokinetics was affected by osthole in SD rat. To estimate the area under the curve (AUC), maximum plasma concentration (Cmax) and apparent clearance (CL/F), indomethacin (10 mg/kg) was given orally combined with osthole (20 mg/kg) in adult SD rat. We found the value of PK on indomethacin, such as the AUC0-∞, was from 176.40 ± 17.29 to 173.74 ± 27.69 μg/ml h-1, Cmax from 9.02 ± 1.24 to 9.89 ± 0.82 μg/ml and CL/F from 0.11 ± 0.01 to 0.12 ± 0.04 mg/kg/h which were unsignificantly changed compared with the control groups. However, the Tmax was prolonged from 2.00 ± 0.00 h to 7.33 ± 1.15 h, and T1/2 increased from 8.38 ± 2.30 h to 11.37 ± 2.11 h. These results indicate that osthole could potentially affect the metabolism of indomethacin in vivo.
Collapse
Affiliation(s)
- Hui He
- College of Pharmacy, Chongqing Medical University, Chongqing, PR China.,Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing, PR China.,Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, Chongqing, PR China
| | - Yuandong Zhang
- College of Pharmacy, Chongqing Medical University, Chongqing, PR China.,Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing, PR China.,Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, Chongqing, PR China
| | - Dezhang Zhao
- College of Pharmacy, Chongqing Medical University, Chongqing, PR China.,Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing, PR China.,Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, Chongqing, PR China
| | - Junhao Jiang
- College of Pharmacy, Chongqing Medical University, Chongqing, PR China.,Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing, PR China.,Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, Chongqing, PR China
| | - Baogang Xie
- College of Pharmacy, Chongqing Medical University, Chongqing, PR China.,Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing, PR China.,Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, Chongqing, PR China
| | - Limei Ma
- College of Pharmacy, Chongqing Medical University, Chongqing, PR China.,Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing, PR China.,Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, Chongqing, PR China
| | - Xueqing Liu
- College of Pharmacy, Chongqing Medical University, Chongqing, PR China.,Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing, PR China.,Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, Chongqing, PR China
| | - Chao Yu
- College of Pharmacy, Chongqing Medical University, Chongqing, PR China.,Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing, PR China.,Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, Chongqing, PR China
| |
Collapse
|
4
|
Yang Q, Sun J, Li C, Zhang H, Xu W, Liu C, Zheng X. Comparative research on the metabolism of metoprolol by four CYP2D6 allelic variants in vitro with LC-MS/MS. J Pharm Biomed Anal 2019; 174:479-485. [PMID: 31228851 DOI: 10.1016/j.jpba.2019.06.016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Revised: 04/28/2019] [Accepted: 06/10/2019] [Indexed: 11/18/2022]
Abstract
Specific study about the effect of cytochrome P450 2D6 (CYP2D6) polymorphisms on the metabolism of clinic drugs is of great significance for drug safety investigation. Here, the interaction between CYP2D6 variants (*1, *2, *10, *39) and metoprolol (MET) was intensively researched in vitro from the aspect of drug-enzyme kinetic study. To obtain quantitative data, α-hydroxymetoprolol (main metabolite of MET) was selected as an ideal analyte and an LC-MS/MS method was adopted for sample determination. Firstly, by selecting suitable internal standard and optimizing separation condition, the LC-MS/MS method was established and validated. Then, the drug-enzyme incubation system was optimized by two parameters: incubation time and amount of enzyme. Lastly, the interaction between CYP2D6 allelic variants and MET was characterized by Km, Vmax and CLint. As a result, four CYP2D6 enzymes displayed diverse Km or Vmax towards MET and the values of CLint showed a wide range from 8.91 to 100%. Relative to CYP2D6*1 (CLint*1 = 100%), CYP2D6*2 demonstrated the second high catalytic activity (CLint*2/*1 = 74.87%) while CYP2D6*39 (CLint*39/*1 = 29.65%) and CYP2D6*10 (CLint*10/*1 = 8.91%) showed minimal catalytic activity. This comprehensive in vitro data suggested the prominent influence of CYP2D6 polymorphisms on the metabolism of MET, which could offer valuable information for personalized administration of MET in clinic.
Collapse
Affiliation(s)
- Qingqing Yang
- Department of Pharmacology, Tianjin Medical University, Tianjin, 300070, China
| | - Jing Sun
- Department of Pharmacology, Tianjin Medical University, Tianjin, 300070, China
| | - Chuan Li
- Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin, 300193, China
| | - Haizhi Zhang
- Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin, 300193, China.
| | - Weiren Xu
- Department of Pharmacology, Tianjin Medical University, Tianjin, 300070, China; Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin, 300193, China.
| | - Changxiao Liu
- Tianjin Center for New Drug Evaluation and Research, State Key Laboratory of Drug Delivery Technology and Pharmaceutics, Tianjin Institute of Pharmaceutical Research, Tianjin, 300193, China
| | - Xuemin Zheng
- Tianjin Key Laboratory of Molecular Design and Drug Discovery, Tianjin Institute of Pharmaceutical Research, Tianjin, 300193, China
| |
Collapse
|